Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. News
  7. Summary
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
End-of-day quote Euronext Paris  -  2022-11-24
1.830 EUR   -5.65%
11/28Biotech Group TMA Pharma's CFO to Leave by 2022-end
MT
11/28Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings
PU
11/28TME Pharma N.V. Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial

08/03/2022 | 02:00am EST

TME Pharma N.V. announced that the first patient was enrolled and has received their first week of treatment in the GLORIA Phase 1/2 clinical trial expansion arm with NOX-A12 combined with radiotherapy and the PD-1 immune checkpoint inhibitor pembrolizumab. Once this first patient of this expansion arm has received a four-week treatment of NOX-A12, radiotherapy, and pembrolizumab, the Data Safety Monitoring Board will convene to determine whether it is safe to recruit the remaining five patients into the arm. The expansion arms of the GLORIA trial will each enroll 6 patients with recruitment ongoing at 6 clinical sites.

The clinical sites are now focused on patient recruitment into the second expansion arm with pembrolizumab after having completed recruitment of patients in the expansion arm with bevacizumab. Initial data from the bevacizumab expansion arm exploring the triple combination of NOX-A12, radiotherapy and bevacizumab reported by the company on June 23, 2022, showed reduced tumor size and radiographic partial response (defined as tumor size reduction of more than 50%) in 100% of evaluable patients, with tumor size reductions ranging from -54.7% to -94.7%. Data from the NOX-A12 dose-escalation part of the clinical trial were reported at ASCO 2022 in June and showed that 90% of patients who received NOX-A12 and radiotherapy achieved tumor size reductions and 40% of patients achieved partial response.

TME Pharma aims to disclose more detailed data, including longer follow-up at a scientific conference later this year.


ę S&P Capital IQ 2022
All news about TME PHARMA N.V.
11/28Biotech Group TMA Pharma's CFO to Leave by 2022-end
MT
11/28Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings
PU
11/28TME Pharma N.V. Announces Executive Changes
CI
11/28TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer
CI
11/23Tme Pharma N : The presentation
PU
11/21TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA..
AQ
11/18TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in ..
CI
11/14Tme pharma announces publication of abstract disclosing positive interim results from b..
AQ
11/14Tme Pharma N : to host key opinion leader webinar
PU
11/11Tme Pharma N : announces publication of abstract disclosing positive interim results from ..
PU
More news
Financials
Sales 2021 0,03 M 0,03 M 0,03 M
Net income 2021 -14,5 M -14,9 M -14,9 M
Net cash 2021 7,02 M 7,24 M 7,24 M
P/E ratio 2021 -1,07x
Yield 2021 -
Capitalization 1,97 M 2,03 M 2,03 M
EV / Sales 2020 405x
EV / Sales 2021 316x
Nbr of Employees 13
Free-Float 12,3%
Chart TME PHARMA N.V.
Duration : Period :
TME Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TME PHARMA N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,45
Average target price
Spread / Average Target -
Managers and Directors
Aram Andrew Mangasarian Chief Business Officer
Bryan Jennings Chief Financial Officer & Statutory Director
Maurizio PetitBon Chairman-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Martine J. van Vugt Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
TME PHARMA N.V.-92.18%2
MODERNA, INC.-31.83%66 521
IQVIA HOLDINGS INC.-22.73%39 470
LONZA GROUP AG-36.15%37 899
ALNYLAM PHARMACEUTICALS, INC.30.08%25 195
SEAGEN INC.-21.48%21 791